Regeneron Pharmaceuticals, Inc. (REGN)

SierraBlue (< 20) Submitted: 11/17/2009 9:49:10 PM : Start Price: $19.84 REGN Score: -7.67

Telechart Pick

Julio60 (< 20) Submitted: 10/5/2009 3:31:29 PM : Start Price: $18.57 REGN Score: -8.18

bullish

mjan706 (< 20) Submitted: 9/22/2008 1:44:10 AM : Start Price: $22.84 REGN Score: -11.42

An Icahn portfolio stock.

CavalierGator (86.77) Submitted: 7/23/2008 5:26:15 PM : Start Price: $18.80 REGN Score: +8.01

The stock was incredibly oversold based on bad data from a phase II trial, especially given the trial's endpoint was ambitious enough that Avastin likely would also have missed it. I think the VEGF trap will still reach the market and the company will be profitable before the end of 2009.

giffman62 (< 20) Submitted: 6/6/2008 2:24:34 AM : Start Price: $15.22 REGN Score: +38.23

Trading too low now, correction is on the horizon.

digitaldad1 (39.33) Submitted: 1/22/2008 5:11:08 PM : Start Price: $23.88 REGN Score: -14.54

Big Pharma now owns 19% at a recent cost of $26.00.
Regeneron shares in the eventual profits while having all the costs covered by payments from this company.
A anti cancer drug promise for tumors is resting on Regeneron and the recent headline says it all:
Regeneron Closes $312 Million Common Stock Sale in Connection with Sanofi-Aventis Collaboration

kurthauer1998 (83.37) Submitted: 1/21/2008 4:41:03 PM : Start Price: $24.00 REGN Score: +14.83

The company's clinical development programs include Interleukin-1 (IL-1) Trap for various inflammatory indications, VEGF Trap for oncology, and VEGF Trap-Eye formulation for eye diseases. The IL-1 Trap is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors. The VEGF Trap is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor. The VEGF Trap-Eye is a form of VEGF Trap for direct injection into the eye, which is tested in a Phase II clinical trial in patients with the neovascular form of age-related macular degeneration and in patients with diabetic macular edema. The company has a collaboration agreement with sanofi-aventis Group for the development of the VEGF Trap in cancer indications and to develop fully-human therapeutic antibodies, as well as with Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

20yrs lot's of gibberish key statistics extremly negative.

GunnarVagotis (95.00) Submitted: 11/29/2007 10:17:59 AM : Start Price: $22.86 REGN Score: -0.51

Regeneron? That's all I need to know. If they had any sack whatsoever the company would be called Regeneronotronix.

corky1872001 (< 20) Submitted: 6/19/2007 7:48:39 PM : Start Price: $19.07 REGN Score: +19.83

treatment for caps

80brown (97.49) Submitted: 5/2/2007 1:04:33 AM : Start Price: $27.92 REGN Score: +13.39

I valuate this one at 383% Intrinsic value.

daviddai (60.22) Submitted: 3/8/2007 12:26:05 PM : Start Price: $19.15 REGN Score: +11.89

The stock has strong therapeutic candidates (interleukin-1 trap and VEGF trap) which, I believe, are likely be approved by FDA in the coming years. This will give them the profit margin that they so desperate need in order to expand their R&D for more drug discovery. They also have very strong R&D team where they publish scientific papers in high impact journals such as Science and Nature. This will ultimately lead to more discoveries of candidates.

mblin13 (33.73) Submitted: 3/1/2007 1:44:09 PM : Start Price: $19.32 REGN Score: +10.76

possible double

hiddenflem (23.30) Submitted: 2/10/2007 6:39:28 AM : Start Price: $19.90 REGN Score: +10.03

Buying because I think VEGF Trap works and I like their deep pipeline.

pkberneburg (< 20) Submitted: 10/19/2006 9:07:21 AM : Start Price: $19.50 REGN Score: +7.34

Small-cap biotech should perform through mid-year 2007